Table 1.
Baseline characteristics of patients with PsA and PsO.
| Item | PsA (n = 74) | PsO (n = 58) |
|---|---|---|
| Male, n (%) | 42(56.7%) | 28 (48.2%) |
| Age, mean (SD), years | 47.0 (13.0) | 44.9 (12.4) |
| PsO duration, years | 13.0 (8.1, 20.5) | 13.0 (7.0,20.0) |
| PsA duration, years | 4.5 (1.4, 9.7) | – |
| ESR, mm/h | 11.0 (4.0, 25.0) | 9.5 (5.0, 15.0) |
| CRP, mg/L | 3.6 (2.1, 13.9) | 3.8 (1.9, 5.9) |
| Psoriasis, n (%) | 70 (94.5%) | 58 (100%) |
| PASI, median (IQR) | 2.2 (0.3, 5.0) | 1.8 (0.7, 4.0) |
| PGA (0–100 mm) | 30 (20, 50) | |
| VAS-PAIN (0–100 mm) | 30 (10,40) | – |
| TJC | 3 (1, 8) | – |
| SJC | 2 (0, 4) | – |
| DAPSA | 13.0 (5.9, 21.5) | – |
| cDAPSA | 11.9 (4.8,19.8) | |
| Minimal disease activity, n (%) | 14 (18.9%) | – |
| Uveitis, n (%) | 5 (6.7%) | 0(0%) |
| Psoriatic nail, n (%) | 38 (51.3%) | 21 (36.2%) |
| Dactylitis, n (%) | 34 (45.9%) | – |
| Enthesitis, n (%) | 4 (5.4%) | |
| Axial involvement, n (%) | 12 (16.2%) | – |
| Treatment | ||
| MTX, n (%) | 63 (85.1%) | 44 (75.8%) |
| NSAIDs, n (%) | 12 (16.2%) | – |
| TNFi, n (%) | 8 (10.8%) | 3 (5.1%) |
| JAKi, n (%) | 4 (5.4%) | 3 (5.1%) |
| IL-17i, n (%) | 1 (1.3%) | 3 (5.1%) |
| MPO–DNA | 0.351 (0.187, 0.652) *† | 0.200 (0.153, 0.429)† |
Values are presented as n (%) for binary variables and mean ± SD or median (IQR) for continuous variables. *Significant difference when compared with patients with PsO, p < 0.05. †Statistical significance when compared with HCs, p < 0.001. PsA duration: the duration of arthritis at baseline. Psoriasis, n (%): the number and percentage of patients with psoriatic skin lesion at baseline. MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; TNFi, tumor necrosis factor inhibitor; JAKi, Janus-activated kinase inhibitor; IL-17i, interleukin-17 inhibitor.